Coherus BioSciences, Inc. (CHRS)

$7.36

-0.04 (-0.54%)
Rating:
Recommendation:
Buy
Symbol CHRS
Price $7.36
Beta 1.207
Volume Avg. 1.03M
Market Cap 569.833M
Shares () -
52 Week Range 5.6-19.32
1y Target Est -
DCF Unlevered CHRS DCF ->
DCF Levered CHRS LDCF ->
ROE -211.68% Strong Sell
ROA -35.43% Strong Sell
Operating Margin -
Debt / Equity 4623.29% Strong Buy
P/E -
P/B 45.26 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CHRS news


Mr. Dennis Lanfear
Healthcare
Biotechnology
NASDAQ Global Market

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.